Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dimerix Limited ( (AU:DXB) ) just unveiled an update.
Dimerix Limited announced a significant licensing agreement with Amicus Therapeutics for its drug candidate DMX-200 in the United States, which could bring up to AU$940 million in payments and royalties. This deal, along with previous agreements, positions Dimerix to potentially receive up to AU$1.4 billion in total payments, strengthening its financial position and supporting ongoing clinical trials and research efforts.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a biopharmaceutical company based in Australia, focused on developing innovative therapies for areas with unmet medical needs. The company is actively involved in the development of its Phase 3 clinical asset in kidney disease, particularly targeting focal segmental glomerulosclerosis (FSGS).
Average Trading Volume: 3,257,544
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$324.1M
Learn more about DXB stock on TipRanks’ Stock Analysis page.